Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 8/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.39 |
| ▸ | HTR2B | P41595 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219238 | 0.84 | HTR2C (0.37) | HTR2CTRPA1HTR2AHTR2B | |
| SCHEMBL6215612 | 0.82 | MEN1 (0.39) | CYP1A2CYP2C19HTR2CTRPA1HTR2A | |
| SCHEMBL6216581 | 0.82 | GRIA1 (0.40) | HTR2C | |
| SCHEMBL6216357 | 0.80 | KDM4E (0.41) | HTR2CHTR2AHTR2B | |
| SCHEMBL6217378 | 0.77 | HTR2C (0.46) | HTR2CHTR2AHTR2B | |
| SCHEMBL6249002 | 0.77 | HTR2C (0.43) | HTR2CHTR2AHTR2B | |
| SCHEMBL6220656 | 0.77 | HTR2C (0.43) | HTR2CHTR2AHTR2B | |
| SCHEMBL13627348 | 0.76 | TRPA1 (0.41) | CYP2C9LMNATP53CYP1A2CYP2C19 | |
| SCHEMBL4477738 | 0.76 | TRPA1 (0.41) | CYP2C9LMNATP53CYP1A2CYP2C19 | |
| SCHEMBL6668455 | 0.76 | CYP1A2 (0.41) | CYP2C9LMNATP53CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414819-B1 | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-12 | — | — | EP | claimed |
| US-6849640-B2 | Therapeutic 1H-pyrido [4,3-b] indoles | PHARMACIA & UPJOHN COMPANY (US) | 2005-02-01 | — | — | US | claimed |
| US-20030060464-A1 | Therapeutic 1H-pyrido [ 4, 3-b ] indoles | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | claimed |
| EP-1414819-B1 | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6849640-B2 | Therapeutic 1H-pyrido [4,3-b] indoles | PHARMACIA & UPJOHN COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030060464-A1 | Therapeutic 1H-pyrido [ 4, 3-b ] indoles | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060464-A1 | Therapeutic 1H-pyrido [ 4, 3-b ] indoles | HTR3B, HTR4, HTR3C | CYP2C9 523/4885LMNA 3654/4885TP53 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.